drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Patient-derived T cells that are transduced in vivo by ESO-T01 to express an anti-BCMA CAR; these CAR-T cells recognize BCMA (TNFRSF17) on multiple myeloma cells and mediate T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Patient T cells are transduced in vivo by a lentiviral vector (ESO-T01) to express an anti-BCMA chimeric antigen receptor. The resulting autologous CAR-T cells recognize BCMA (TNFRSF17) on multiple myeloma cells, leading to T‑cell activation, cytokine release, proliferation, and targeted cytotoxic killing of BCMA-expressing tumor cells.
drug_name
Autologous anti-BCMA CAR-T cells (in vivo generated)
nct_id_drug_ref
NCT06691685